公开(公告)号：US20220211838A1

公开(公告)日：2022-07-07

申请号：US17665704

申请日：2022-02-07

Applicant: CureVac AG

Inventor： Cornelia OOSTVOGELS ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHWENDT

IPC: A61K39/145 ,  A61K39/155 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

公开(公告)号：US20210162037A1

公开(公告)日：2021-06-03

申请号：US16098834

申请日：2017-05-04

Applicant: CureVac AG

Inventor： Edith JASNY ,  Susanne RAUCH ,  Kim Ellen SCHWENDT ,  Benjamin PETSCH ,  Karen SLOBOD

IPC: A61K39/145

Abstract: The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.

公开(公告)号：US20210401966A1

公开(公告)日：2021-12-30

申请号：US17469313

申请日：2021-09-08

Applicant: CureVac AG

Inventor： Susanne RAUCH ,  Kim Ellen SCHWENDT ,  Benjamin PETSCH

IPC: A61K39/125 ,  C07K14/005 ,  A61P31/12 ,  A61K9/00

Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

公开(公告)号：US20220249654A1

公开(公告)日：2022-08-11

申请号：US17665808

申请日：2022-02-07

Applicant: CureVac AG

Inventor： Cornelia OOSTVOGELS ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHWENDT

IPC: A61K39/215 ,  A61P31/14 ,  A61K9/00 ,  A61K9/127 ,  A61K31/7105 ,  A61K31/7115 ,  C12N15/67

Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

公开(公告)号：US20220211841A1

公开(公告)日：2022-07-07

申请号：US17665772

申请日：2022-02-07

Applicant: CureVac AG

Inventor： Cornelia OOSTVOGELS ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHWENDT

IPC: A61K39/295 ,  C12N7/00 ,  C07K14/005 ,  A61K9/51 ,  A61K47/69 ,  A61K39/215 ,  A61K39/145 ,  A61P31/14 ,  A61P31/16

Abstract: The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

公开(公告)号：US20200163878A1

公开(公告)日：2020-05-28

申请号：US16345299

申请日：2017-10-26

Applicant: CureVac AG ,  Acuitas Therapeutics Inc.

Inventor： Patrick BAUMHOF ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Michael J. HOPE ,  Edith JASNY ,  Sandra LAZZARO ,  Paulo Jia Ching LIN ,  Johannes LUTZ ,  Barbara MUI ,  Benjamin PETSCH ,  Susanne RAUCH ,  Kim Ellen SCHWENDT ,  Ying TAM

IPC: A61K9/127 ,  A61K39/39 ,  A61K9/19 ,  A61P37/02 ,  A61K31/7105 ,  A61P31/16 ,  A61K39/145 ,  A61K47/69 ,  A61K47/14

Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.